Impact of anti- @entity1722 therapy on @entity1349 in @entity1722 -overexpressing @entity0 XXXX with brain metastases.

@entity1 @entity0 @entity9433 @entity262 @entity1349 @entity1722
BACKGROUND: Trastuzumab-based therapy after diagnosis of brain metastases (BM) may improve survival due to prolonged @entity262 control. We investigated whether @entity9433 may yield additional survival benefit. METHODS: Eighty @entity1 with BM from @entity1722 -positive @entity0 were identified. Karnofsky Performance Score (KPS) of at least 70 was required. We included a control group of 37 @entity1 treated before 2003, when continuation of trastuzumab after diagnosis of BM was not yet recommended. Remainders received either trastuzumab or @entity9433 and trastuzumab (either concomitantly or sequentially) with or without chemotherapy. RESULTS: Median @entity1349 ( @entity1349 ) in @entity1 receiving trastuzumab after diagnosis of BM was 13 months; corresponding numbers were 9 months in @entity1 treated with chemotherapy, and 3 months with radiotherapy alone. Median @entity1349 was not reached in the @entity9433 group. Addition of @entity9433 prolonged @entity1349 over trastuzumab alone (P=0.002). After correction for potential confounders, @entity9433 therapy remained an independent positive predictor for survival (HR 0.279; P=0.012). INTERPRETATION: This retrospective single-centre study suggests that the introduction of @entity9433 improved survival in @entity1 with BM from @entity1722 -positive @entity0 . @entity1 with KPS >= 70 may benefit when treated with @entity9433 in addition to trastuzumab after completion of local therapy.
